ANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap Up – Here’s Why

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $58.38, but opened at $61.58. ANI Pharmaceuticals shares last traded at $60.38, with a volume of 39,524 shares traded.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on ANIP shares. HC Wainwright reiterated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. Piper Sandler started coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 target price for the company. Raymond James upped their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. StockNews.com lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Finally, Truist Financial upped their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $77.33.

ANI Pharmaceuticals Trading Up 5.2 %

The firm’s 50-day simple moving average is $58.66 and its 200-day simple moving average is $61.52. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $1.29 billion, a PE ratio of 52.51 and a beta of 0.71.

Institutional Trading of ANI Pharmaceuticals

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of ANI Pharmaceuticals by 1.4% in the first quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company’s stock worth $90,314,000 after purchasing an additional 17,460 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of ANI Pharmaceuticals by 3.5% in the second quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company’s stock worth $40,132,000 after purchasing an additional 21,053 shares during the last quarter. Global Alpha Capital Management Ltd. grew its stake in shares of ANI Pharmaceuticals by 1.8% in the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock worth $32,005,000 after purchasing an additional 9,500 shares during the last quarter. Millennium Management LLC grew its stake in shares of ANI Pharmaceuticals by 1,005.8% in the second quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock worth $14,651,000 after purchasing an additional 209,272 shares during the last quarter. Finally, Thompson Siegel & Walmsley LLC grew its stake in shares of ANI Pharmaceuticals by 1.5% in the second quarter. Thompson Siegel & Walmsley LLC now owns 195,743 shares of the specialty pharmaceutical company’s stock worth $12,465,000 after purchasing an additional 2,986 shares during the last quarter. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.